Can Testosterone Injections Cause Atrial Flutter/Fibrillation?
Yes, testosterone intramuscular injections can increase the risk of atrial fibrillation (and by extension atrial flutter), particularly in older men with hypogonadism, though the evidence shows this risk varies by patient population and baseline testosterone levels.
Evidence for Increased Atrial Fibrillation Risk
The most recent and highest-quality evidence demonstrates a clear association between testosterone therapy and atrial fibrillation in specific populations:
In hypogonadal cis men treated with testosterone, a 2025 large-scale propensity-matched study of 117,908 men found a 27% increased risk of atrial fibrillation (HR: 1.27 [1.22-1.32]) after 5 years of testosterone therapy compared to untreated men 1. This represents the strongest evidence for harm.
In healthy older men with high-normal testosterone levels, a 2024 analysis of 4,570 men aged ≥70 years found that those with testosterone in the highest quintiles had nearly double the risk of incident AF (Q4:Q3 HR=1.91; Q5:Q3 HR=1.98) 2. This suggests a non-linear relationship where high-normal testosterone concentrations independently increase AF risk.
Mechanistic Understanding
The arrhythmogenic effects appear mediated through several pathways:
- Enhanced adrenergic activity: Testosterone increases β1-adrenergic receptor expression and reduces G protein-coupled receptor kinase-2, making cardiac tissue more susceptible to catecholamine-induced arrhythmias 3
- Altered ion channel expression: Testosterone upregulates Cav 1.2 (calcium channels) while downregulating Kv 4.2 (potassium channels), creating an electrophysiological substrate for arrhythmias 3
- Shortened action potential duration: Unlike estrogen which prolongs APD (antiarrhythmic), testosterone shortens it, creating a proarrhythmic substrate 4
Important Caveats and Clinical Context
The relationship is not straightforward:
Low testosterone is also problematic: Multiple studies suggest testosterone deficiency itself contributes to AF incidence 5. This creates a U-shaped risk curve where both very low and high-normal testosterone levels increase AF risk.
Intramuscular formulations may carry higher risk: IM injections produce supraphysiologic peaks in testosterone levels, which correlate with adverse effects. The 2004 NEJM guideline noted that IM testosterone is associated with greater erythrocytosis risk (43.8% vs 15.4% for transdermal) 6, and erythrocytosis increases blood viscosity and cardiovascular risk.
Population matters: The 2025 study found no increased AF risk in transgender men treated with testosterone compared to untreated controls 1, suggesting baseline cardiovascular risk profiles modify the effect.
Clinical Monitoring Recommendations
For patients receiving testosterone IM injections:
- Monitor for new palpitations, irregular pulse, or symptoms of AF/flutter at each visit
- Obtain baseline ECG before initiating therapy in men >60 years or with cardiovascular risk factors
- Check hematocrit regularly (the 2004 NEJM guideline recommends monitoring since erythrocytosis occurred in 43.8% of IM testosterone users) 6
- Consider lower doses or alternative formulations (transdermal) in older men or those with cardiovascular risk factors
- Be particularly vigilant in the first year of therapy when most cardiovascular events occur 7
Common pitfall: Assuming all cardiovascular risks are equal across formulations. IM testosterone produces supraphysiologic peaks that may drive both erythrocytosis and arrhythmia risk more than steady-state transdermal preparations.
Risk-Benefit Context
While the 2020 American College of Physicians guideline found that most observational studies did not identify increased cardiovascular mortality with testosterone 7, and the 2025 study actually showed reduced myocardial infarction risk (HR: 0.94) 1, the consistent signal for increased atrial fibrillation across multiple recent high-quality studies cannot be ignored. The absolute risk increase appears modest but clinically significant, particularly in older men where AF substantially impacts quality of life and stroke risk.
The evidence does not support withholding testosterone in appropriately selected hypogonadal men, but it does mandate informed consent about AF risk and vigilant monitoring, especially with IM formulations.